You are currently viewing a new version of our website. To view the old version click .
Biology and Life Sciences Forum
  • Abstract
  • Open Access

14 March 2022

Cytokinins from Plants to Humans †

,
and
1
Department of Bioinformatics, Biocenter, University of Würzburg, Am Hubland, 97074 Würzburg, Germany
2
Department of Biochemistry, Faculty of Pharmacy, University of Minia, Minia 61519, Egypt
3
Department of Life and Environmental Sciences, College of Natural and Health Sciences, Zayed University, Dubai P.O. Box 4783, United Arab Emirates
*
Authors to whom correspondence should be addressed.
This article belongs to the Proceedings The 2nd International Electronic Conference on Nutrients

Abstract

The plant hormones cytokinins play a major role in cell division and cell differentiation. They affect organogenesis in plant cell cultures and contribute to many other physiological and developmental processes in plants. Kinetin was first discovered 60 years ago and was the first known member of cytokinines. On the market, kinetin is formulated by cosmetic companies to combat anti-aging and is topically applied without a defined dosage or instructions on its use. Until now, no systemic formulations with specific doses and mechanisms have been produced. Some studies have reported the effect of kinetin on different human diseases , such as its ability to prevent age-related changes in human skin by protecting the DNA in skin cells from damage (antioxidant effects) and decreasing skin water loss, in addition to its therapeutic potential in the treatment of the human splicing disease, familial dysautonomia, in vitro. Our research with kinetin began with studying its activity in plants , followed by screening for the systemic activity of kinetin in mammalian cells in vitro, where we showed for the first time that kinetin exerts anticytotoxic, antioxidant, antigenotoxic and antiapoptotic activities in different cell lines from different origins. The promising in vitro results allowed us to continue to the in vivo stage of the investigation, where we examined the safety of kinetin for systemic administration in rats.

Author Contributions

Conceptualization, E.M.O., T.D. and M.N.; validation, formal analysis, E.M.O. and M.N.; investigation, E.M.O. and M.N.; writing—review and editing, E.M.O. and T.D.; supervision, T.D.; project administration, T.D., E.M.O. and M.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.